Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)

被引：0
|
作者：
Warren, Richard B. [1 ]
de Bruin-Weller, Marjolein [2 ]
Tsianakas, Athanasios [3 ]
Khemis, Abdallah [4 ]
Szepietowski, Jacek C. [5 ]
Hong, H. Chih-Ho [6 ]
Armengol, Clara [7 ]
Falques, Meritxell [7 ]
Agell, Helena [7 ]
Massana, Eric [7 ]
Gil, Esther Garcia [7 ]
Weidinger, Stephan [8 ]
机构：
[1] Univ Manchester, Northern Care Alliance NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, England
[2] Univ Med Ctr Utrecht, Utrecht, Netherlands
[3] Fachklin Bad Bentheim, Bad Bentheim, Germany
[4] Polyclin St George Grp Kantys, Dermatol, Nice, France
[5] Med Univ, Wroclaw, Poland
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Almirall SA, Barcelona, Spain
[8] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
lebrikizumab; topical corticosteroids; investigator global assessment; eczema area and severity index; pruritis numeric rating scale;
D O I：
10.1093/bjd/ljae266.005
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
619
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Carrascosa, Jose Manuel
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [42] Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to cyclosporine A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFE)
    de Bruin-Weller, Marjolein
    Thaci, Diamant
    Smith, Catherine
    Radin, Allen
    Zhang, Rick
    Gadkari, Abhijit
    Eckert, Laurent
    Hultsch, Thomas
    Pirozzi, Gianluca
    Graham, Neil M. H.
    Shumel, Brad
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 14 - 14
  • [43] Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5)
    Simpson, E.
    Forman, S.
    Silverberg, J.
    Zirwas, M.
    Maverakis, E.
    Han, G.
    Guttman-Yassky, E.
    Marnell, D.
    Bissonnette, R.
    Waibel, J.
    Nunes, F.
    DeLozier, A.
    Angle, R.
    Holzwarth, K.
    Goldblum, O.
    Zhong, J.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E97
  • [44] LEBRIKIZUMAB IMPROVES CLINICAL MANIFESTATIONS AND PATIENT-REPORTED OUTCOMES IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: PHASE 2B STUDY RESULTS
    Ali, Z.
    Guttman-Yassky, E.
    Blauvelt, A.
    Eichenfield, L.
    Paller, A.
    Armstrong, A.
    Drew, J.
    Gopalan, R.
    Simpson, E.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 32 - 32
  • [45] The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial
    Mehrbani, Mehrzad
    Choopani, Rasool
    Fekri, Alireza
    Mehrabani, Mitra
    Mosaddegh, Mahmoud
    Mehrabani, Mehrnaz
    JOURNAL OF ETHNOPHARMACOLOGY, 2015, 172 : 325 - 332
  • [46] Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials
    Mendes-Bastos, Pedro
    Ladizinski, Barry
    Guttman-Yassky, Emma
    Jiang, Ping
    Liu, John
    Prajapati, Vimal H.
    Simpson, Eric L.
    Vigna, Namita
    Teixeira, Henrique D.
    Barbarot, Sebastien
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 784 - 791
  • [47] The effect of dupilumab on vaccine antibody responses in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial
    Blauvelt, A.
    Simpson, E.
    Wu, R.
    Akinlade, B.
    Graham, N.
    Pirozzi, G.
    Evans, R.
    ALLERGY, 2016, 71 : 95 - 95
  • [48] Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
    Blauvelt, Andrew
    Simpson, Eric L.
    Tyring, Stephen K.
    Purcell, Lisa A.
    Shumel, Brad
    Petro, Christopher D.
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Evans, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 158 - +
  • [49] Treatment withdrawal and retreatment with upadacitinib in patients with moderate-to-severe atopic dermatitis from a phase IIb, randomized, controlled trial
    Reich, K.
    Thaci, D.
    Papp, K.
    Anderson, J.
    Hu, X.
    Gu, Y.
    Teixeira, H.
    Guttman-Yassky, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E98 - E99
  • [50] Sulthiame improves sleep quality in patients with moderate-to-severe obstructive sleep apnea- a randomized placebo-controlled trial
    Theliander, K.
    Hedner, J.
    Strassberger, C.
    Stenlof, K.
    Grote, L.
    Zou, D.
    JOURNAL OF SLEEP RESEARCH, 2022, 31
12345